← All trials
NCT05870059
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 2, 2022
- Primary completion
- Jul 4, 2022
- Completion date
- Nov 16, 2022
- First posted
- May 23, 2023
- Last posted
- May 23, 2023
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ziauddin UniversityLead sponsor
- Ziauddin UniversityReponsible party - principal investigator
- Ziauddin UniversitySponsor investigator
- Ziauddin UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.